Taysha Gene Therapies TSHA
NASDAQ TSHA
$4.63 -0.11 (-2.32%)
At close: Oct 2, 2026 · 4:00 PM EDT

Taysha Gene Therapies (TSHA) Other Accumulated Expenses (2019 - 2026)

Updated

Taysha Gene Therapies (TSHA) posted Other Accumulated Expenses of $355,000 for Q2 2026, down 55.6% from $800,000 a year earlier and down 54.7% from the prior quarter.

Analysis

Taysha Gene Therapies (TSHA) Other Accumulated Expenses (2019 - 2026) Analysis & Trends

At the end of FY2025, Taysha Gene Therapies' Other Accumulated Expenses came in at $777,000, up 3.3% from FY2024.

  • Annual Other Accumulated Expenses has increased for three consecutive years, with a five-year compound annual growth rate of 53.6% (FY2020 to FY2025).
  • In prior years, Taysha Gene Therapies' Other Accumulated Expenses was $752,000 in FY2024 (+4.0%), $723,000 in FY2023 (+11.2%), $650,000 in FY2022 (-56.4%) and $1.49 million in FY2021.
  • The Q2 2026 figure stands as the lowest quarterly Other Accumulated Expenses since Q1 2021.
  • On a year-over-year basis, Other Accumulated Expenses increased in five of the last eight quarters, with an average decline of 3.8%.
  • The strongest year-over-year quarter for Other Accumulated Expenses in the past five years was Q3 2021, with growth of 285.6%; the weakest was Q3 2023, with a decline of 56.9%.
  • According to Business Quant data, Other Accumulated Expenses for the three prior quarters was $784,000 (Q1 2026), $777,000 (Q4 2025) and $749,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Taysha Gene Therapies 1.51 Bn 1.51 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 355,000.00
Mar 31, 2026 784,000.00
Dec 31, 2025 777,000.00
Sep 30, 2025 749,000.00
Jun 30, 2025 800,000.00
Mar 31, 2025 806,000.00
Dec 31, 2024 752,000.00
Sep 30, 2024 876,000.00
Jun 30, 2024 777,000.00
Mar 31, 2024 781,000.00
Dec 31, 2023 723,000.00
Sep 30, 2023 681,000.00
Jun 30, 2023 684,000.00
Mar 31, 2023 690,000.00
Dec 31, 2022 650,000.00
Sep 30, 2022 1.58 Mn
Jun 30, 2022 1.48 Mn
Mar 31, 2022 1.59 Mn
Dec 31, 2021 1.49 Mn
Sep 30, 2021 779,000.00
API Access

Taysha Gene Therapies Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=TSHA&period=max&api_key=YOUR_API_KEY